186 related articles for article (PubMed ID: 31640478)
1. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor.
Adams DF; Watkins MS; Durette L; Laliberté J; Goulet F; Debien E; Frazier KS; Mellal N; Chen L; Shi W; Thomas R; Hu E
Toxicol Pathol; 2020 Feb; 48(2):362-378. PubMed ID: 31640478
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Beck J; Henschel C; Chou J; Lin A; Del Balzo U
Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
[TBL] [Abstract][Full Text] [Related]
4. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects.
Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A
Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511
[TBL] [Abstract][Full Text] [Related]
5. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
[TBL] [Abstract][Full Text] [Related]
6. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
Holdstock L; Meadowcroft AM; Maier R; Johnson BM; Jones D; Rastogi A; Zeig S; Lepore JJ; Cobitz AR
J Am Soc Nephrol; 2016 Apr; 27(4):1234-44. PubMed ID: 26494831
[TBL] [Abstract][Full Text] [Related]
7. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis.
Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV
BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects.
Hara K; Takahashi N; Wakamatsu A; Caltabiano S
Drug Metab Pharmacokinet; 2015 Dec; 30(6):410-8. PubMed ID: 26643993
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Carcinogenic Potential of Enarodustat (JTZ-951), a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor, in 26-Week Tg.rasH2 Mouse Study and 2-Year Sprague-Dawley Rat Study.
Kemmochi Y; Toyoda K; Ishida T; Yasui Y; Shoda T
Int J Toxicol; 2023 Dec; 42(6):489-503. PubMed ID: 37480334
[TBL] [Abstract][Full Text] [Related]
10. HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury.
Billin AN; Honeycutt SE; McDougal AV; Kerr JP; Chen Z; Freudenberg JM; Rajpal DK; Luo G; Kramer HF; Geske RS; Fang F; Yao B; Clark RV; Lepore J; Cobitz A; Miller R; Nosaka K; Hinken AC; Russell AJ
Skelet Muscle; 2018 Nov; 8(1):35. PubMed ID: 30424786
[TBL] [Abstract][Full Text] [Related]
11. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients.
Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A
Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555
[TBL] [Abstract][Full Text] [Related]
12. Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease.
Johnson HN; Prasad-Reddy L
Ann Pharmacother; 2024 Apr; ():10600280241241563. PubMed ID: 38616529
[TBL] [Abstract][Full Text] [Related]
13. Daprodustat: First Approval.
Dhillon S
Drugs; 2020 Sep; 80(14):1491-1497. PubMed ID: 32880805
[TBL] [Abstract][Full Text] [Related]
14. First evidence of the incorporation of daprodustat and other hypoxia-inducible factor stabilizers into equine hair by passive transfer based on segmental quantitative analysis.
Ishii H; Shibuya M; Kusano K; Sone Y; Kamiya T; Wakuno A; Ito H; Miyata K; Yamada M; Leung GN
J Pharm Biomed Anal; 2023 Oct; 235():115600. PubMed ID: 37516063
[TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacokinetics of Daprodustat: Results of an Absorption, Distribution, and Excretion Study With Intravenous Microtracer and Concomitant Oral Doses for Bioavailability Determination.
Mahar KM; Caltabiano S; Andrews S; Ramanjineyulu B; Chen L; Young G; Pereira A; Lindsay AC; van den Berg F; Cobitz AR
Clin Pharmacol Drug Dev; 2021 Dec; 10(12):1419-1431. PubMed ID: 34713596
[TBL] [Abstract][Full Text] [Related]
16. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
Doggrell SA
Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents.
Kowalski H; Hoivik D; Rabinowitz M
Toxicol Pathol; 2023 Jan; 51(1-2):56-60. PubMed ID: 37158494
[TBL] [Abstract][Full Text] [Related]
18. In vitro studies of hypoxia inducible factor-prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control.
Philip M; Karakka Kal AK; Subhahar MB; Karatt TK; Mathew B; Perwad Z
Drug Test Anal; 2022 Feb; 14(2):317-348. PubMed ID: 34714596
[TBL] [Abstract][Full Text] [Related]
19. A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat.
Yamada M; Osamura M; Ogura H; Onoue T; Wakamatsu A; Numachi Y; Caltabiano S; Mahar KM
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):978-984. PubMed ID: 32250021
[TBL] [Abstract][Full Text] [Related]
20. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Fukui K; Shinozaki Y; Kobayashi H; Deai K; Yoshiuchi H; Matsui T; Matsuo A; Matsushita M; Tanaka T; Nangaku M
Eur J Pharmacol; 2019 Sep; 859():172532. PubMed ID: 31301309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
